- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00006249
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma.
PURPOSE: Randomized phase III trial to determine the effectiveness of interferon alfa in treating patients who have undergone surgery for stage III melanoma.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
- Compare the effect of adjuvant therapy with pegylated interferon alfa vs observation, in terms of distant metastases-free survival, in patients with previously resected stage III melanoma.
- Compare the overall survival in these patients after treatment with pegylated interferon alfa vs observation.
- Determine the toxicity of pegylated interferon alfa in these patients.
- Determine the compliance of these patients treated with pegylated interferon alfa.
- Compare the quality of life in these patients after treatment with pegylated interferon alfa vs observation.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to type of nodal involvement (N1 vs N2), number of positive nodes (1 vs 2-4 vs 5 or more vs not assessed), Breslow primary (T1-2 vs T3 vs T4 vs unknown), ulceration of primary tumor (absent vs present vs unknown), sex, and center. Patients are randomized to one of two treatment arms.
- Arm I: Patients receive pegylated interferon alfa subcutaneously weekly for 5 years.
- Arm II: Patients undergo observation only. Treatment continues in the absence of distant metastases or unacceptable toxicity.
Quality of life is assessed at baseline, and then at months 3, 12, 24, 36, 48, and 60.
Patients are followed every 6 months for 5 years.
PROJECTED ACCRUAL: A total of 1,200 patients (600 per treatment arm) will be accrued for this study within 1.5-2 years.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, D-13122
- Robert Roessle Klinik
-
Bochum 1, Alemanha, D-44791
- Saint Josef Hospital
-
Dortmund, Alemanha, 44123
- Stadt. Kliniken
-
Erlangen, Alemanha, D-91054
- Universitaet Erlangen
-
Goettingen, Alemanha, D-37075
- Georg August Universitaet
-
Hamburg, Alemanha, D-22765
- Haematologisch-Onkologische Praxis Altona
-
Heidelberg, Alemanha, D-69115
- Universitaets-Hautklinik Heidelberg
-
Leipzig, Alemanha, D-04103
- Universitaet Leipzig - Chirurgische Klinik und Poliklinik I
-
Magdeburg, Alemanha, D-39120
- Otto - Von - Guericke - Universitaet Magdeburg
-
Mannheim, Alemanha, D-68135
- Klinikum der Stadt Mannheim
-
Wuerzburg, Alemanha, D-97080
- Universitaet Wuerzburg/Hautkrankheiten
-
-
-
-
-
Newcastle, Austrália, NSW 2300
- David Maddison Clincial Sciences
-
-
Victoria
-
East Melbourne, Victoria, Austrália, 8006
- Peter MacCallum Cancer Institute
-
Heidelberg West, Victoria, Austrália, 3081
- Austin and Repatriation Medical Centre
-
-
Western Australia
-
Perth, Western Australia, Austrália, 6000
- Royal Perth Hospital
-
Perth, Western Australia, Austrália, 6009
- Sir Charles Gairdner Hospital, Perth
-
-
-
-
-
Sofia, Bulgária, 1756
- National Centre of Oncology
-
-
-
-
-
Brussels, Bélgica, 1200
- Cliniques Universitaires Saint-Luc
-
Brussels, Bélgica, 1000
- Institut Jules Bordet
-
Brussels, Bélgica, 1070
- Hopital Universitaire Erasme
-
Edegem, Bélgica, B-2650
- Universitair Ziekenhuis Antwerpen
-
Gosselies, Bélgica, 6041
- Clinique Notre Dame de Grâce
-
Leuven, Bélgica, B-3000
- U.Z. Gasthuisberg
-
-
-
-
-
Zagreb, Croácia, 10000
- University Hospital Sestre milosrdnice
-
-
-
-
-
Ljubljana, Eslovênia, Sl-1000
- Institute of Oncology, Ljubljana
-
-
-
-
-
Madrid, Espanha, 28041
- Hospital Universitario 12 De Octubre
-
Zaragoza, Espanha, 50009
- Hospital Clinico Universitario
-
-
-
-
-
Tallinn, Estônia, 11619
- North-Estonian Regional Hospital Cancer Centre
-
-
-
-
-
Amiens, França, 80054
- Centre Hospitalier Universitare d'Amens
-
Besancon, França, 25030
- CHR de Besancon - Hopital Saint-Jacques
-
Bordeaux, França, 33075
- Hopital Saint André
-
Boulogne Billancourt, França, F-92104
- CHU Ambroise Pare
-
Grenoble, França, 38043
- Chr De Grenoble - La Tronche
-
Lille, França, 59037
- Centre Hospitalier Regional et Universitaire de Lille
-
Limoges, França, 87042
- Centre Hospital Regional Universitaire de Limoges
-
Lyon, França, 69373
- Centre Leon Berard
-
Montpellier, França, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Montpellier, França, 34295
- Hopital St. Eloi
-
Nice, França, F-06202
- Hopital L'Archet - 2
-
Paris, França, 75018
- Hôpital Bichat - Claude Bernard
-
Paris, França, 75475
- Hopital Saint-Louis
-
Pessac, França, 33604
- Hôpital Haut Lévêque
-
Reims, França, 51092
- Centre Hospitalier Universitaire
-
Rennes, França, 35042
- Centre Eugene Marquis
-
Saint Cloud, França, 92211
- Centre René Huguenin
-
Saint Priest en Jarez, França, 42277
- Centre Hospitalier Regional et Universitaire de Saint-Etienne
-
Strasbourg, França, 67091
- Hopitaux Universitaire de Strasbourg
-
Thionville, França, 57126
- Centre Hospitalier Regional Metz Thionville
-
Tours, França, 37044
- Centre Hospitalier Universitaire Bretonneau de Tours
-
Vandoeuvre-les-Nancy, França, 54511
- Centre Alexis Vautrin
-
Villejuif, França, F-94805
- Institut Gustave Roussy
-
-
-
-
-
Amsterdam, Holanda, 1007 MB
- Vrije Universiteit Medisch Centrum
-
Leiden, Holanda, 2300 CA
- Leiden University Medical Center
-
Nijmegen, Holanda, NL-6500 HB
- University Medical Center Nijmegen
-
Rotterdam, Holanda, 3075 EA
- Erasmus University Medical Center
-
Utrecht, Holanda, 3584 CX
- Academisch Ziekenhuis Utrecht
-
-
-
-
-
Haifa, Israel, 31096
- Rambam Medical Center
-
Holon, Israel, 58100
- Wolfson Medical Center
-
Tel-Aviv, Israel, 64239
- Tel-Aviv Sourasky Medical Center
-
-
-
-
-
Aviano, Itália, 33081
- Centro di Riferimento Oncologico - Aviano
-
Firenze, Itália, I-50011
- Ospendale S.M. Annunziata-A.S.DI Firenze
-
Genoa (Genova), Itália, 16132
- Istituto nazionale Per la Ricerca sul Cancro
-
Milano, Itália, 20141
- European Institute of Oncology - Chemo Prevention
-
Milano (Milan), Itália, 20133
- Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
-
Naples, Itália, 80131
- Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
-
Rome, Itália, 00161
- Istituto Regina Elena
-
Torino, Itália, 10126
- Universita degli Studi di Torino
-
-
-
-
-
Istanbul, Peru, 34296
- Vakif Gureba Training Hospital
-
Izmir, Peru, 35220
- Ege University Medical School
-
-
-
-
-
Poznan, Polônia, 61 866
- Great Poland Cancer Center
-
Warsaw, Polônia, 02-781
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
-
-
-
-
-
Lisbon, Portugal, 1099-023 Codex
- Instituto Portugues de Oncologia de Francisco Gentil - Centro de Lisboa
-
Porto, Portugal, 4200
- Instituto Portugues de Oncologia Centro do Porto, SA
-
-
-
-
-
Birmingham, Reino Unido, B29 6JD
- Selly Oak Hospital at University Hospital NHS Trust
-
Oxford, Reino Unido, OX3 7LJ
- Churchill Hospital
-
-
England
-
Bristol, England, Reino Unido, BS2 8ED
- Bristol Haematology and Oncology centre
-
Cambridge, England, Reino Unido, CB2 2QQ
- Addenbrooke's NHS Trust
-
Cheltenham, England, Reino Unido, GL53 7AN
- Cheltenham General Hospital
-
Exeter, England, Reino Unido, EX2 5DW
- Royal Devon and Exeter Hospital
-
Guildford, England, Reino Unido, GU2 5XX
- Royal Surrey County Hospital
-
Hull, England, Reino Unido, HU8 9HE
- Princess Royal Hospital
-
Leeds, England, Reino Unido, LS9 7TF
- St. James's Hospital
-
Leicester, England, Reino Unido, LE1 5WW
- Leicester Royal Infirmary
-
London, England, Reino Unido, SW3 6JJ
- Royal Marsden NHS Trust
-
London, England, Reino Unido, NW3 2QG
- Royal Free Hospital
-
London, England, Reino Unido, SW17 0QT
- St. George's Hospital
-
London, England, Reino Unido, EC1A 7BE
- Saint Bartholomew's Hospital
-
London, England, Reino Unido, SE1 9RT
- Guy's and St. Thomas' Hospitals NHS Trust
-
Merseyside, England, Reino Unido, CH63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Newcastle Upon Tyne, England, Reino Unido, NE4 6BE
- Newcastle General Hospital
-
Salisbury, England, Reino Unido, SP2 8BJ
- Salisbury District Hospital
-
Sheffield, England, Reino Unido, S1O 2SJ
- Weston Park Hospital
-
Southampton, England, Reino Unido, SO16 6YD
- Southampton General Hospital
-
Sutton, England, Reino Unido, SM2 5PT
- Royal Marsden Hospital
-
Westcliff-On-Sea, England, Reino Unido, SS0 0RY
- Southend NHS Trust Hospital
-
-
Northern Ireland
-
Belfast, Northern Ireland, Reino Unido, BT9 7AB
- Belfast City Hospital Trust
-
-
Scotland
-
Dundee, Scotland, Reino Unido, DD1 9SY
- Ninewells Hospital and Medical School
-
Glasgow, Scotland, Reino Unido, G11 6NT
- Western Infirmary
-
-
Wales
-
Cardiff, Wales, Reino Unido, CF4 7XL
- Velindre Cancer Center at Velinde Hospital
-
-
-
-
-
Prague (Praha), República Checa, 128 08
- Charles University Hospital
-
-
-
-
-
Aarau, Suíça, 5001
- Kantonspital Aarau
-
Bern, Suíça, CH-3010
- Inselspital, Bern
-
Chur, Suíça, CH-7000
- Ratisches Kantons und Regionalspital
-
Zurich, Suíça, CH-8091
- UniversitaetsSpital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
Histologically confirmed previously resected stage III primary cutaneous melanoma or unknown primary with regional lymph node involvement
N1 disease
- Microscopic, nonpalpable nodal involvement
- Primary melanoma of any stage with clinically inapparent N1 regional lymph node metastases (T1-4, N1, M0) detected by elective lymph node dissection or sentinel node biopsy
N2 disease
- Palpable nodal involvement with synchronous primary melanoma or apparent nodal disease after prior excision (any pT, N2, M0)
- Regional lymph node recurrence at any interval after surgery for primary melanoma of any depth (T1-4, rN2, M0)
- Complete resection of primary melanoma with adequate surgical margins
- Full lymphadenectomy must be performed within 70 days of study
- No mucous membrane melanoma or ocular melanoma
- No evidence of distant or nonregional lymph node metastases or in transit metastases (even if previously resected)
- No incompletely resected disease due to gross extracapsular extension
PATIENT CHARACTERISTICS:
Age:
- 18 to 70
Performance status:
- ECOG 0-1
Life expectancy:
- Not specified
Hematopoietic:
- WBC at least 3,000/mm^3
- Platelet count greater than 100,000/mm^3
- Hemoglobin at least 9 g/dL
Hepatic:
- SGOT and SGPT less than 2 times upper limit of normal
- No active hepatitis
Renal:
- Creatinine less than 2.0 mg/dL
Cardiovascular:
No severe cardiovascular disease including the following:
- Arrhythmias requiring chronic treatment
- Congestive heart failure (New York Heart Association class III or IV)
- Symptomatic ischemic heart disease
Other:
- No other prior malignancy within the past 5 years except surgically cured nonmelanomatous skin cancer or carcinoma in situ of the cervix
- No thyroid dysfunction unresponsive to therapy
- No uncontrolled diabetes mellitus
- No active autoimmune disease
- No active and/or uncontrolled infection
- No history of neuropsychiatric disorder requiring hospitalization
- No known active alcohol or drug abuse
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior interferon alfa
- No prior immunotherapy for melanoma
- No other concurrent immunologic or biologic therapy
- No concurrent colony stimulating factors including epoetin alfa and filgrastim (G-CSF)
Chemotherapy:
- No prior chemotherapy for melanoma
- No concurrent chemotherapy
Endocrine therapy:
- No prior hormonal therapy for melanoma
- No concurrent hormonal therapy
- No concurrent chronic systemic corticosteroid therapy
Radiotherapy:
- No prior radiotherapy for melanoma
- No concurrent radiotherapy
Surgery:
- See Disease Characteristics
- Recovered from any prior recent surgery
Other:
- At least 30 days since other prior experimental therapy
- No other concurrent investigational drugs
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Sem intervenção: observation
5 years observation + 5 years follow up
|
|
Experimental: pegylated interferon alfa
5 years pegylated interferon alfa + 5 years follow up
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
distant-metastasis free-survival (DMFS)
Prazo: from randomization
|
distant-metastasis free-survival (DMFS) after randomization
|
from randomization
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
survival
Prazo: from randomization till death
|
duration of survival: time from randomization until death, whatever the cause
|
from randomization till death
|
toxicity
Prazo: from randomization
|
toxicity
|
from randomization
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
quality of life
Prazo: from randomization
|
Quality of life evaluation
|
from randomization
|
Colaboradores e Investigadores
Investigadores
- Cadeira de estudo: Alexander M. M. Eggermont, MD, PhD, Daniel Den Hoed Cancer Center at Erasmus Medical Center
Publicações e links úteis
Publicações Gerais
- Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Sales F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012 Jan;48(2):218-25. doi: 10.1016/j.ejca.2011.09.028. Epub 2011 Nov 5.
- Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: long-term results at 7.6-years follow-up. [Abstract] J Clin Oncol 29 (Suppl 15): A-8506b, 2011.
- Bouwhuis MG, Suciu S, Testori A, Kruit WH, Sales F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol. 2010 May 10;28(14):2460-6. doi: 10.1200/JCO.2009.24.6264. Epub 2010 Apr 12.
- Eggermont AM, Bouwhuis MG, Kruit WH, Testori A, ten Hagen T, Yver A, Xu C. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). Cancer Chemother Pharmacol. 2010 Mar;65(4):671-7. doi: 10.1007/s00280-009-1072-z. Epub 2009 Jul 21.
- Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Sales F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009 Jun 20;27(18):2916-23. doi: 10.1200/JCO.2008.20.2069. Epub 2009 May 11. Erratum In: J Clin Oncol. 2009 Sep 20;27(27):4630. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.
- Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer. 2009 Dec;45(18):3189-97. doi: 10.1016/j.ejca.2009.09.004. Epub 2009 Sep 28.
- Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, MacKie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117-126. doi: 10.1016/S0140-6736(08)61033-8.
- Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-8504, 473s, 2007.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias por Tipo Histológico
- Neoplasias
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Tumores Neuroendócrinos
- Nevos e Melanomas
- Melanoma
- Efeitos Fisiológicos das Drogas
- Agentes Anti-Infecciosos
- Antivirais
- Agentes Antineoplásicos
- Fatores imunológicos
- Interferons
- Interferon-alfa
Outros números de identificação do estudo
- EORTC-18991
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Melanoma (pele)
-
Utah State UniversityAtivo, não recrutandoDistúrbio de Escoriação (Skin-Picking)Estados Unidos
-
3MRescindidoAplicação de pós-produto de redução bacteriana da Skin FloraEstados Unidos
-
Karolinska InstitutetRegion StockholmConcluídoTricotilomania | Distúrbio de Escoriação (Skin-Picking)Suécia
Ensaios clínicos em Terapia adjuvante
-
Pamukkale UniversityConcluído
-
University of PennsylvaniaRescindidoInfecção Recorrente por Clostridium DifficileEstados Unidos
-
Azienda Ospedaliera Universitaria Integrata VeronaConcluído
-
University of Roma La SapienzaConcluídoFalha no implante dentário | Mucosite OralItália
-
University of Applied Sciences and Arts of Southern...Vrije Universiteit Brussel; Universiteit Antwerpen; THIM - die internationale...Concluído
-
NeuroTronik Inc.DesconhecidoInsuficiência Cardíaca AgudaPanamá
-
University of PennsylvaniaRescindidoInfecção Grave por Clostridium Difficile | Infecção Grave Complicada/Fulminante por Clostridium DifficileEstados Unidos
-
CellMedX CorporationNutrasource Pharmaceutical and Nutraceutical Services, Inc.Concluído
-
Columbia UniversityRescindido
-
The Cleveland ClinicRecrutamentoEstrabismo | AmbliopiaEstados Unidos